Cite
HARVARD Citation
Pick, M. et al. (2018). Daratumumab resistance is frequent in advanced‐stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis. European journal of haematology. pp. 494-501. [Online].